Abstract
X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLH–GHD, OMIM # 307200) is a primary immunodeficiency disorder characterized by pan-hypogammaglobulinemia and isolated growth hormone deficiency. The disease, which is only known to occur in a single family, shares many features with X-linked agammaglobulinemia (XLA, OMIM # 300300). The current review summarizes the clinical, laboratory and genetic features of the disease as they have unfolded over the past quarter century since its description.
Similar content being viewed by others
References
Fleisher TA, White RM, Broder S, Nissley SP, Blaese RM, Mulvihill JJ, Olive G, Waldmann TA. X-linked hypogammaglobulinemia and isolated growth hormone deficiency. N Engl J Med 1980;302:1429–34.
Conley ME, Burks AW, Herrod HG, Puck JM. Molecular analysis of X-linked agammaglobulinemia with growth hormone deficiency. J Pediatr 1991;119:392–7.
Duriez B, Duquesnoy P, Dastot F, Bougneres P, Amselem S, Goossens M. An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency. FEBS Lett 1994;346:165–70.
Monafo V, Maghnie M, Terracciano L, Valtorta A, Massa M, Severi F. X-linked agammaglobulinemia and isolated growth hormone deficiency. Acta Paediatr Scand 1991;80:563–6.
Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226–33.
Wagner DK, Marti GE, Jaffe ES, Straus SE, Nelson DL, Fleisher TA. Lymphocyte analysis in a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency after development of echovirus dermatomyositis and meningoencephalitis. Int Arch Allergy Appl Immunol 1989;89:143–8.
Wilfert CM, Buckley RH, Mohanakumar T, Griffith JF, Katz SL, Whisnant JK, Eggleston PA, Moore M, Treadwell E, Oxman MN, Rosen FS. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med 1977;296:1485–9.
Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64:145–56.
Kovach SJ, Fischer AC, Katzman PJ, Salloum RM, Ettinghausen SE, Madeb R, Koniaris LG. Inflammatory myofibroblastic tumors. J Surg Oncol 2006;94:385–91.
Imanguli MM, et al. J Oral Maxillofac Surg in press accepted for publication, 2006.
Lavilla P, Gil A, Rodriguez MC, Dupla ML, Pintado V, Fontan G. X-linked agammaglobulinemia and gastric adenocarcinoma. Cancer 1993;72:1528–31.
van der Meer JW, Weening RS, Schellekens PT, van Munster IP, Nagengast FM. Colorectal cancer in patients with X-linked agammaglobulinaemia. Lancet 1993;341:1439–40.
Kerstens PJ, Endtz HP, Meis JF, Oyen WJ, Koopman RJ, van den Broek PJ, van der Meer JW. Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia. Eur J Clin Microbiol Infect Dis 1992;11:842–7.
Chusid MJ, Coleman CM, Dunne WM. Chronic asymptomatic Campylobacter bacteremia in a boy with X-linked hypogammaglobulinemia. Pediatr Infect Dis J 1987;6:943–4.
Stewart DM, Tian L, Notarangelo LD, Nelson DL. Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency. Curr Opin Allergy Clin Immunol 2005;5:510–2.
Stewart DM, Notarangelo LD, Kurman CC, Staudt LM, Nelson DL. Molecular genetic analysis of X-linked hypogammaglobulinemia and isolated growth hormone deficiency. J Immunol 1995;155:2770–4.
Notarangelo LD, Wagner DK, Schwieterman WD, Camerino G, Fleisher TA, Nelson DL. Restriction fragment polymorphism analysis of patients with X-linked agammaglobulinemia and isolated growth hormone deficiency. In: Albertini A, Paoletti R, Reisfeld RA, editors. Molecular probes: technology and medical applications. New York: Raven Press; 1989. p. 143–8.
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature 1996;380:152–4.
Packer BR, Yeager M, Staats B, Welch R, Crenshaw A, Kiley M, Eckert A, Beerman M, Miller E, Bergen A, Rothman N, Strausberg R, Chanock SJ. A public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528–32.
Pruitt KD, Maglott DR. RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res 2001;29:137–40.
Watanabe S, Take H, Takeda K, Yu ZX, Iwata N, Kajigaya S. Characterization of the CIN85 adaptor protein and identification of components involved in CIN85 complexes. Biochem Biophys Res Commun 2000;278:167–74.
Miyazaki Y, Sun X, Uchida H, Zhang J, Nimer S. MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties. Oncogene 1996;13:1721–9.
Sitz KV, Burks AW, Williams LW, Kemp SF, Steele RW. Confirmation of X-linked hypogammaglobulinemia with isolated growth hormone deficiency as a disease entity. J Pediatr 1990;116:292–4.
Abo K, Nishio H, Lee MJ, Tsuzuki D, Takahashi T, Yoshida S, Nakajima T, Matsuo M, Sumino K. A novel single basepair insertion in exon 6 of the Bruton’s tyrosine kinase (Btk) gene from a Japanese X-linked agammaglobulinemia patient with growth hormone insufficiency. Hum Mutat 1998;11:336.
Buzi F, Notarangelo LD, Plebani A, Duse M, Parolini O, Monteleone M, Ugazio AG. X-linked agammaglobulinemia, growth hormone deficiency and delay of growth and puberty. Acta Paediatr 1994;83:99–102.
Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, Cordon-Cardo C, Mao S, Pandolfi PP, Nimer SD. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002;17:437–49.
Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y, Kai H. The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 2002;62:6579–86.
Bennani-Baiti IM, Cooke NE, Liebhaber SA. Physical linkage of the human growth hormone gene cluster and the CD79b (Ig beta/B29) gene. Genomics 1998;48:258–64.
Su Y, Liebhaber SA, Cooke NE. The human growth hormone gene cluster locus control region supports position-independent pituitary- and placenta-specific expression in the transgenic mouse. J Biol Chem 2000;275:7902–9.
Gong S, Nussenzweig MC. Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Science 1996;272:411–4.
Kouro T, Nagata K, Takaki S, Nisitani S, Hirano M, Wahl MI, Witte ON, Karasuyama H, Takatsu K. Bruton’s tyrosine kinase is required for signaling the CD79b-mediated pro-B to pre-B cell transition. Int Immunol 2001;13:485–93.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stewart, D.M., Tian, L., Notarangelo, L.D. et al. X-linked hypogammaglobulinemia and isolated growth hormone deficiency: an update. Immunol Res 38, 391–399 (2007). https://doi.org/10.1007/s12026-007-0052-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12026-007-0052-9